Elements DNA
Published research · Immune

ARA-290

Cibinetide

Eleven-residue erythropoietin-derived peptide, lyophilized

7 papers · 2013–2024 · 7 journals

What the research explores

The peptide exists to dissect a receptor question, and its literature follows that. Areas of study include:

  • Innate repair receptor engagement — the heteromeric complex of the EPO receptor and the beta common receptor (CD131), and how a helix B mimetic binds it.
  • Dissociation of signaling arms — comparing tissue-directed signaling against the haematopoietic response driven by the EPO receptor homodimer.
  • Inflammatory cell signaling in vitro, using the peptide as a receptor-selective tool.
  • Structure-activity relationships of helix B mimetics — which residues of the eleven are load-bearing.
  • Peptide stability and clearance kinetics relative to the full-length hormone.

Supplied as a characterized reagent. We make no claim about outcomes in any organism.

References

A reference list, not evidence. Inclusion means a paper discusses the compound — not that it supports any use, and not that it describes this product.

  1. 2024

    1. The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury

      Liu G, Liang J, Li W, et al.

      International immunopharmacology

      PMID 38943972doi 10.1016/j.intimp.2024.112452

    2. Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke

      Wang RL, Yang ZH, Huang YY, et al.

      CNS neuroscience & therapeutics

      PMID 38488446doi 10.1111/cns.14676

  2. 2022

    1. A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan

      Winicki NM, Nanavati AP, Morrell CH, et al.

      Frontiers in cardiovascular medicine

      PMID 36741836doi 10.3389/fcvm.2022.1096887

  3. 2021

    1. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice

      Awida Z, Bachar A, Saed H, et al.

      International journal of molecular sciences

      PMID 35008482doi 10.3390/ijms23010055

  4. 2018

    1. Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus

      Huang B, Jiang J, Luo B, et al.

      Journal of cellular and molecular medicine

      PMID 29570934doi 10.1111/jcmm.13608

  5. 2015

    1. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin

      Collino M, Thiemermann C, Cerami A, et al.

      Pharmacology & therapeutics

      PMID 25728128doi 10.1016/j.pharmthera.2015.02.005

  6. 2013

    1. Editorial

      Tracey KJ

      Molecular medicine (Cambridge, Mass.)

      PMID 24178588doi 10.2119/molmed.2013.00135

More research in immune

For laboratory and research use only · Not for human or veterinary consumption · Not evaluated by the FDA